Changes in bone turnover markers and association with decreased total bone mineral density (tBMD) in treatment-naive subjects taking lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine

Prospective studies have reported a 2-6% BMD decrease through Wk96 after antiretroviral therapy (ART) initiation. It is unclear whether early changes in bone turnover markers predict bone loss following ART initiation. We evaluated changes in bone turnover markers in patients initiating lopinavir/ri...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2013-01, Vol.18, p.A15-A15
Main Authors: Brown, T T, Fredrick, L, Warren, D, Toh, L K, Renjifo, B, Trinh, R, Qaqish, R
Format: Article
Language:English
Subjects:
Human immunodeficiency virus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prospective studies have reported a 2-6% BMD decrease through Wk96 after antiretroviral therapy (ART) initiation. It is unclear whether early changes in bone turnover markers predict bone loss following ART initiation. We evaluated changes in bone turnover markers in patients initiating lopinavir/ritonavir plus raltegravir or lopinavir/ritonavir plus tenofovir/emtricitabine, and tested association of baseline marker levels and early changes from baseline with clinically significant bone loss at Wk96. ART-naive, HIV-infected adults were randomized to receive lopinavir/ritonavir 400/100 mg twice daily with raltegravir 400 mg twice daily or tenofovir/emtricitabine 300/200 mg once daily. Whole body dualenergy X-ray absorptiometry (DXA) scans assessed tBMD. Early changes in CTx predicted [> or=]5% tBMD decrease at Wk96. Studies are needed to establish its utility to predict tBMD loss with ART initiation.
ISSN:1359-6535